Research advances in sofosbuvir for treatment of chronic hepatitis C
10.3969/j.issn.1001-5256.2016.04.044
- VernacularTitle:索非布韦治疗慢性丙型肝炎的研究进展
- Author:
Huanyan PENG
1
;
Erna YANG
;
Dianxing SUN
Author Information
1. Bethune International Peace Hospital of People′s Liberation Army, Shijiazhuang 050082, China
- Publication Type:Research Article
- Keywords:
hepatitis C, chronic；antiviral agents；sofosbuvir；review
- From:
Journal of Clinical Hepatology
2016;32(4):798-801
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, new changes have occurred in the treatment of chronic hepatitis C. Direct-acting antiviral agents have shown powerful efficacy in the treatment of active hepatitis C, and even refractory hepatitis C shows a high continuous virologic response. Among these direct-acting antiviral agents, sofosbuvir (SOF) has the advantages of short course of antiviral treatment and high response rate, and some patients with certain hepatitis C genotypes have no need to receive interferon therapy. This article introduces the mechanism of action, current status of clinical application, and major adverse effects of SOF, and points out its promising future in patients with refractory hepatitis C.
